Saturday at ASCO 2019 will see Gilead’s Kite unveil end of phase 1 data from ZUMA-3, a phase 1/2 study of the company’s investigational KTE-X19, an anti-CD19 CAR-T cell therapy in adults with relapsed/refractory acute lymphoblastic leukaemia.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,